Spruce Biosciences (SPRB)
NASDAQ:SPRB
SPRB Stock Chart & Stats
$66.01
--
Market closed
$66.01
--
Day’s Range― - ―
52-Week Range$4.32 - $240.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)988.68K
Market Cap
$90.57M
Enterprise Value-$9.86M
Total Cash (Recent Filing)$48.91M
Total Debt (Recent Filing)$736.00K
Price to Earnings (P/E)―
Beta-10.18
Next Earnings
May 13, 2026EPS Estimate
-8.82Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.73
Shares Outstanding1,372,043
10 Day Avg. Volume2,922,716
30 Day Avg. Volume988,676
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.57
Price to Sales (P/S)0.00
P/FCF Ratio-2.00
Enterprise Value/Market Cap-0.11
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit1.97K
Enterprise Value/Ebitda0.28
Forecast
1Y Price Target
$217.67Price Target Upside229.75% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-32.34
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy And Biomarker ResponseExtended clinical data showing normalization of a cerebrospinal fluid biomarker alongside stabilization of cognitive and adaptive functions and improvement in organ measures supports the treatment's potential clinical benefit and market value.
Non-dilutive Funding OpportunityEligibility for a Priority Review Voucher presents a meaningful source of non-dilutive funding if approval is obtained, which could strengthen financial position without immediate equity dilution.
Regulatory Approval PathwayFDA concurrence that combined clinical and natural history data and a cerebrospinal fluid biomarker could support a surrogate endpoint paves the way for an accelerated approval pathway and lowers regulatory approval risk.
Bears Say
Filing Timeline And Execution RiskA revision to the filing timeline increases the likelihood that more funding will be needed before commercialization, raising execution and timing uncertainty for the approval process.
Funding Requirement RiskAnalyst notes that additional capital may be required to support operations through regulatory approval and United States market entry, creating a risk of cash shortfall.
Potential Dilution From FinancingThe need for extra capital to bridge to approval and launch could force equity or other dilutive financing, which may reduce shareholder value and increase sensitivity to financing announcements.
Spruce Biosciences News
SPRB FAQ
What was Spruce Biosciences’s price range in the past 12 months?
Spruce Biosciences lowest stock price was $4.32 and its highest was $240.00 in the past 12 months.
What is Spruce Biosciences’s market cap?
Spruce Biosciences’s market cap is $90.57M.
When is Spruce Biosciences’s upcoming earnings report date?
Spruce Biosciences’s upcoming earnings report date is May 13, 2026 which is in 33 days.
How were Spruce Biosciences’s earnings last quarter?
Spruce Biosciences released its earnings results on Mar 09, 2026. The company reported -$8.73 earnings per share for the quarter, beating the consensus estimate of -$9.158 by $0.428.
Is Spruce Biosciences overvalued?
According to Wall Street analysts Spruce Biosciences’s price is currently Undervalued.
Does Spruce Biosciences pay dividends?
Spruce Biosciences does not currently pay dividends.
What is Spruce Biosciences’s EPS estimate?
Spruce Biosciences’s EPS estimate is -8.82.
How many shares outstanding does Spruce Biosciences have?
Spruce Biosciences has 1,372,043 shares outstanding.
What happened to Spruce Biosciences’s price movement after its last earnings report?
Spruce Biosciences reported an EPS of -$8.73 in its last earnings report, beating expectations of -$9.158. Following the earnings report the stock price went up 11.169%.
Which hedge fund is a major shareholder of Spruce Biosciences?
Currently, no hedge funds are holding shares in SPRB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Spruce Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$217.67 (229.75% Upside)
$217.67 (229.75% Upside)
Hedge Fund Trend
Decreased
By 16.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 6.7%
Last 30 Days ▼ 6.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
312.60%
12-Months-Change
Fundamentals
Return on Equity
-305.39%
Trailing 12-Months
Asset Growth
-76.48%
Trailing 12-Months
Company Description
Spruce Biosciences
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.
SPRB Stock 12 Month Forecast
Average Price Target
$217.67
▲(229.75% Upside)